Regional nodal irradiation examining the clinical implications of randomized trials

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 39, Issue 1, 2016, Pages 90-91

  Shah, Chirag ^a,b   Khan, Atif ^c   Arthur, Douglas ^d   Wazer, David ^e,f   Mantz, Constantine ^g   Verma, Vivek ^h   Vicini, Frank ^g  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BROWN UNIVERSITY   (United States)

^g 21ST CENTURY ONCOLOGY   (United States)

^h UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT RADIOTHERAPY; ADVERSE EFFECTS; AXILLA; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE; LYMPHEDEMA; MASTECTOMY; PATHOLOGY; PROCEDURES; RADIATION PNEUMONITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE;

AXILLA; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC IRRADIATION; LYMPHEDEMA; MASTECTOMY; RADIATION PNEUMONITIS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 84957841396     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000250     Document Type: Note

References (14)

1. Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373:307-316.
2. Poortmans PS, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373:317-327.
3. Buchholz TA, Woodward WA, Duan Z, et al. Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and one to three positive axillary lymph nodes. Int J Radiat Oncol Biol Phys. 2008;71:1022-1027.
4. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes as recommended in international consensus reports? A subgroup analysis of the DBCG 82b&c randomized trials. Radiother Oncol. 2007;82:247-253.
5. Burstein HJ, Morrow M. Nodal irradiation after breast-cancer surgery in the era of effective adjuvant treatment. N Engl J Med. 2015;373:379-381.
6. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23:3686-3696.
7. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol. 2003;21:1431-1439.
8. Dawood S, Gonzalez-Angulo AM, Woodward W, et al. Value of adjuvant radiation therapy in breast cancer patients with one to three positive lymph nodes undergoing a modified radical mastectomy and systemic therapy. J Clin Oncol. 2009;15:507.
9. Truong PT, Jones SO, Kader HA, et al. Patients with t1 to t2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast conserving surgery and whole-breast radiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:357-364.
10. Peterson DJ, Truong PT, Sadek BT, et al. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer. Ann Surg Oncol. 2014;21:3490-3496.
11. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60-62.
12. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with positive sentinel lymph node meta-stases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426-432.
13. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomized, multicenter, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15: 1303-1310.
14. Early Breast Cancer Trialists' Collaborative Group. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127-2135.